Hosted on MSN1mon
Novel PET approach identifies early signs of pulmonary arterial hypertension
A new molecular imaging technique— 18 F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early ...
Pulmonary Hypertension News2d
MTMR7 protein shows promise as PAH treatment in mice
Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...
Managed Healthcare Executive11d
PET Imaging Could Help Track PAH Onset, Therapy Response, Study Finds
New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.
The American Journal of Managed Care1y
2022 ESC/ERS Guideline-Recommended Management of Pulmonary Arterial Hypertension and Agents Under Clinical Development
It is important for clinicians to implement measures that avoid fluid retention in patients with PAH. 5 If signs of right-sided HF and edema develop, it is recommended that clinicians prescribe ...
Medscape20d
Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension
Fifty patients with pulmonary hypertension of varying causes (28 with PAH, five in WHO group 3 and 17 in WHO group 4) underwent drug administration during right-heart catheterization. Subjects ...
Nature5y
Bosentan for SSc: long-term outcomes in PAH and efficacy for Raynaud phenomenon
Bosentan is known to be effective for SSc-associated pulmonary arterial hypertension (PAH), but data regarding long-term outcomes are scarce. In addition, although it has been shown to prevent the ...
European Medical Journal7d
Sotatercept Shows Long-Term Benefit in Pulmonary Arterial Hypertension Treatment
The ongoing SOTERIA study suggests that sotatercept provides a favourable long-term safety and efficacy profile for adults with pulmonary hypertension.